GLP-1 drugs for obesity
GLP-1 based medicines such as semaglutide and tirzepatide for weight management.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 96, 106, 155, 232, 344.
New guidelines and consensus this year
- Integrating incretin-based therapies into comprehensive obesity care: an EASO position statementLancet Reg Health Eur2026 Nov
- Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause SocietyMaturitas2026 Oct
- Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practiceFront Endocrinol (Lausanne)2026
- Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus StatementLancet Diabetes Endocrinol2026 Sep
- Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statementCancer2026 Aug 15
All papers from the last 12 months
3,169 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Discovery of Fisetin as a potent and cell-active ACVR2A inhibitorBioorg Med Chem Lett2027 JanPMID 42801961
- Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional studyLibyan J Med2026 Dec 31PMID 42886550
- Peptide LKLKLL is a more effective component of Akkermansia muciniphila which regulate glucolipid metabolism through GLP-1/GIP dual modulationGut Microbes2026 Dec 31PMID 42473065
- Christensenella massiliensis reduces kynurenine levels and alleviates obesity and related metabolic disorders in model miceGut Microbes2026 Dec 31PMID 42434935
- A novel bile salt hydrolase-producing Ligilactobacillus salivarius prevents diet-induced obesity via regulation of bile acid metabolism and glucagon-like peptide 1 restorationGut Microbes2026 Dec 31PMID 42092775
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialLancet2026 Dec 20PMID 41275875RCT
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medicationsJ Diabetes Metab Disord2026 DecPMID 42871568Review
- GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific riskN Am Spine Soc J2026 DecPMID 42871273Review
- Neuroendocrine regulation of appetite and energy balance in metabolic disordersIBRO Neurosci Rep2026 DecPMID 42861025Review
- Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetesObes Pillars2026 DecPMID 42831032
More internal medicine trends
All specialties →Cardiovascular-kidney-metabolic syndrome
The linked burden of cardiovascular disease, kidney disease, diabetes and obesity.
Large language models in clinical care
Chatbots and large language models used for clinical questions, documentation and patient communication.
Polypharmacy
Use of many medicines at once and its risks.
Frailty assessment
Tools and scores to identify frailty in older adults.
Deprescribing
Planned reduction or stopping of medicines that may no longer benefit the patient.
Key point: Deprescribing statins is suggested for older adults at end of life; continuation is suggested for primary or secondary prevention otherwise.
Hospital at home
Acute hospital-level care delivered in the patient's home.
Key point: Home hospitalization presents an effective strategy for comprehensive heart failure management, reducing hospital-related complications and promoting patient-centered care.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("GLP-1"[tiab] OR semaglutide[tiab] OR tirzepatide[tiab] OR liraglutide[tiab]) AND obesity[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.